



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/469712/2018

European Medicines Agency decision

P/0233/2018

of 15 August 2018

on the refusal of a modification of an agreed paediatric investigation plan for roxadustat (EMEA-001557-PIP01-13-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Only the English text is authentic.



European Medicines Agency decision

P/0233/2018

of 15 August 2018

on the refusal of a modification of an agreed paediatric investigation plan for roxadustat (EMA-001557-PIP01-13-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0020/2015 issued on 30 January 2015 and the decision P/0275/2017 issued on 4 October 2017,

Having regard to the application submitted by Astellas Pharma Europe B.V. on 6 April 2018 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 29 June 2018, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the refusal of changes to the agreed paediatric investigation plan and to the waiver.
- (2) It is therefore appropriate to adopt a decision on the refusal of changes to the agreed paediatric investigation plan, including changes to the waiver.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for roxadustat, film-coated tablet, oral use, including changes to the waiver, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, are hereby refused.

Article 2, 3

This decision is addressed to Astellas Pharma Europe B.V., Sylviusweg 62, 2333 BE – Leiden, The Netherlands.

EMA/PDCO/231286/2018

London, 29 June 2018

Opinion of the Paediatric Committee on the refusal of a modification of an agreed Paediatric Investigation Plan

EMA-001557-PIP01-13-M02

Scope of the application

Active substance(s):

Roxadustat

Condition(s):

Treatment of anaemia due to chronic disorders

Pharmaceutical form(s):

Film-coated tablet

Route(s) of administration:

Oral use

Name / corporate name of the PIP applicant:

Astellas Pharma Europe B.V.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Astellas Pharma Europe B.V. submitted to the European Medicines Agency on 6 April 2018 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/0020/2015 issued on 30 January 2015 and the decision P/0275/2017 issued on 4 October 2017.

The application for modification proposed changes to the agreed paediatric investigation plan and to the waiver.

The procedure started on 2 May 2018.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends, as set out in the appended summary report:
 - to refuse the changes proposed by the applicant regarding the paediatric investigation plan and the scope of the waiver.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver remain unchanged and are set out in the Annex I.
3. The scientific conclusions and the grounds for refusal are set out in the summary report appended to this opinion.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition

Treatment of anaemia due to chronic disorders

The waiver applies to:

- the paediatric population from birth to less than 6 months of age;
- for film-coated tablet for oral use;
- on the grounds that the specific medicinal product is likely to be unsafe.

2. Paediatric investigation plan

2.1. Condition

Treatment of anaemia due to chronic disorders

2.1.1. Indication(s) targeted by the PIP

Treatment of anaemia associated with chronic kidney disease (CKD)

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 6 months to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Film-coated tablet

2.1.4. Measures

Area	Number of measures	Description
Quality-related studies	1	Study 1 Development of lower strength of the film-coated tablet not containing azo dyes.
Non-clinical studies	1	Study 2 Definitive juvenile toxicity study. (ASP1517-PED-NON-CLIN-01)
Clinical studies	3	Study 3 Open label, randomised, 3-way cross-over study to evaluate the relative bioavailability, PK, food effect and palatability of the paediatric formulation versus adult tablet. (ASP1517-PED-CLIN-01)

		Study 4 Open-label, randomised, age-group adjusted starting dose, active-controlled trial to evaluate PK/PD, safety and efficacy of roxadustat compared to recombinant human erythropoietin or its analogues in ESA-naïve children from 6 months to less than 18 years of age with anaemia due to chronic kidney disease stages 3, 4 and 5. (ASP1517-PED-CLIN-03) Study 5 Open-label, randomised, age-group adjusted starting dose, active-controlled trial to evaluate PK/PD, safety and efficacy of roxadustat compared to recombinant human erythropoietin or its analogues in children from 6 months to less than 18 years of age with anaemia due to chronic kidney disease stages 3, 4 and 5 on stable ESA treatment. (ASP1517-PED-CLIN-04)
Extrapolation, modelling and simulation studies	0	Not applicable.
Other studies	0	Not applicable.
Other measures	0	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By July 2023
Deferral for one or more measures contained in the paediatric investigation plan:	Yes